Tau, a microtubule-associated protein (MAP) that is predominantly expressed in neurons, promotes tubulin assembly into microtubules (MTs) and stabilizes them in vitro, and presumably also in vivo. It is mainly localized in axons and forms short cross-bridges between individual MTs (1-4), and has been thought to play an important role in maintaining neuronal morphology (5-7). However, the central nervous system of tau-deficient mice produced by gene targeting appeared to be normal, although the number of MTs was significantly reduced in some small caliber axons (8). In addition, according to one report (9), axonal elongation of the neurons cultured from taudeficient brains is not affected.
Tau, a microtubule-associated protein (MAP) that is predominantly expressed in neurons, promotes tubulin assembly into microtubules (MTs) and stabilizes them in vitro, and presumably also in vivo. It is mainly localized in axons and forms short cross-bridges between individual MTs (1-4), and has been thought to play an important role in maintaining neuronal morphology (5) (6) (7) . However, the central nervous system of tau-deficient mice produced by gene targeting appeared to be normal, although the number of MTs was significantly reduced in some small caliber axons (8) . In addition, according to one report (9) , axonal elongation of the neurons cultured from taudeficient brains is not affected.
The hyperphosphorylated form of tau is the major constituent of paired helical filaments (PHFs), unusual fibrils that accumulate in subsets of neurons in brains affected by Alzheimer's disease (AD) (10) . PHF-like fibrils are also one of the striking characteristics of frontotemporal dementia and parkinsonism linked to chromosome 17 , which is caused by a number of missense and intronic mutations in the tau gene (11) (12) (13) . Because abundance of the unusual fibrils well correlates with the extent of neuronal loss, these findings suggest that tau is involved in the cascade to neuronal death in AD and FTDP-17.
Gem GTPase is a small GTP-binding protein of the ras superfamily, the major function of which has remained to be determined (14, 15) . Overexpression of mouse Gem GTPase induced invasive pseudohyphal growth in Saccharomyces cerevisiae (16) .
Two functions of Gem GTPase have recently been reported: the inhibition of voltagegated calcium-channel activity and a negative regulation of the Rho-Rho kinase pathway for cytoskeletal organization. Gem GTPase regulates the expression of α-subunit of voltage-gated calcium channels at the plasma membrane by binding to ß-subunit (17) . Gem GTPase also regulates the cytoskeletal organization mediated by Rho kinase (ROK) ß. Overexpression of Gem GTPase inhibits ROK-mediated stress fiber formation, focal adhesion, and neurite retraction (18) . In addition to ROKß, Gem GTPase has been shown to bind to KIF-9, a kinesin-like protein (19) , and to Gmip, a RhoGAP-containing protein (20) .
To clarify an as yet unidentified role(s) of tau, gene expression was compared between the brains of wild-type (tau+/+) and tau-deficient (tau-/-) mice, using a highdensity oligonucleotide array. We found that the expression of Gem GTPase is significantly increased in the brains of eight-week-old tau-deficient mice. Here, we report that the overexpression of Gem GTPase induces elongation of CHO cells, and that tau antagonizes this effect, the activity of which is attributable to the MT-binding domain.
EXPERIMENTAL PROCEDURES
Animals-Male tau-deficient mice (8) that were backcrossed to C57Bl/6J mice for seven generations and wild-type (wt) control mice were killed at one week, eight weeks, and ten months of age. Tau-deficient mice grew normally, but displayed some muscle weakness at ~10 weeks of age (21) .
RNA extraction and array hybridization-RNA was extracted from the cerebrum using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's recommended protocol. RNA from the cerebral cortices of five tau-deficient mice or five age-matched wt mice was combined into one sample (~250 µg of total RNA) for each time point. Poly (A) + RNA was isolated from the RNA samples using an Oligotex mRNA isolation kits (Takara Bio, Kyoto, Japan). Biotinylated cRNAs were prepared according to the Affymetrix protocol. Mu11K oligonucleotide arrays (Affymetrix, Santa Clara, CA) were prehybridized, hybridized, washed, and stained as recommended by the manufacturer, using a GeneChip Fluidics Station 400 (Affymetrix).
Criteria for selection of abnormally expressed genes-Analysis of the array data was performed essentially as described previously (22) . The present study was designed to minimize potential experimental confounds as follows. First, a pooled sample was subjected to the GeneChip analysis, and subsequently the result was confirmed by examining individual variability. Second, each sample was measured in duplicate to minimize false positives caused by chip hybridization variability. Four comparisons of control vs. tau-deficient mice were performed using two hybridization replicates for each of the pooled samples for wt and tau-deficient groups (22) . Finally, some of the findings were confirmed by quantitative RT-PCR. Using the Affymetrix algorithm (23) and multiple analysis comparison software for assessing gene expression differences, mRNAs that were increased or decreased in tau-deficient mice relative to wt mice in all four comparisons (see ref 22 ; high stringency analysis) were identified. Default setting in the GeneChip3.1 software was used to assign a particular mRNA to be increased, decreased or unchanged.
Verification of altered expression by reverse transcriptase-coupled PCR (RT-
PCR)-Total RNA was extracted from the brains of eight-week-old wt and tau-deficient mice using the TRIzol reagent. Contaminating genomic DNA was removed with RQ1 RNase-Free DNase I (Promega, Madison, WI). Quantitative RT-PCR was carried out to confirm the altered gene expression, as described previously (24), except for the use of [α-32 P] dCTP as tracer. Primers were designed to yield ~350-500 bp cDNA fragments. The nucleotide sequences of the primers are given in Table S1 .
Complementary DNA for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was simultaneously amplified as a control. Each PCR cycle consisted of 1 min at 94 ÚC, 1 min at 55 ÚC, and 1 min at 72 ÚC. PCR amplification was performed for 22~24 cycles for the mRNAs suggested as candidates by GeneChip analysis, and 17 cycles for GAPDH mRNA. These ranges of cycling provided the exponential amplification required for quantification of each mRNA. After amplification, the products were separated on a polyacrylamide gel (6%). The gel was then dried and exposed to an imaging plate, which was subjected to laser image analysis (Fujix BAS 2000; Fuji Film, Tokyo, Japan). All values obtained were normalized against the levels of GAPDH mRNA.
Mammalian expression vectors-Total mouse brain RNA was reverse-transcribed using random hexamers as primers, as described elsewhere (24) . Gem GTPase cDNA was amplified by PCR from cDNAs thus prepared, using oligonucleotide primers anchored with EcoRI (5'end) and SalI (3'end) restriction sites. The forward primer was 5'-CCCCAGGAATTCCCACTCTGAATAATGTCACCATGCG-3', which is in frame with the carboxyl terminal region of GFP, and the reverse primer was 5'-GCTCGAGTCGACCTAGAGCACAGACAGGTCATGGC. PCR was carried out for 35 cycles with each consisting of 1 min at 94 ÚC, 1 min at 55 ÚC, and 4 min at 72ÚC.
The PCR products were then digested with EcoRI and SalI, and subcloned into the expression vector pEGFP-C3 (BD Biosciences, Palo Alto, CA). The entire nucleotide sequence of Gem GTPase cDNAs was determined by the dideoxynucleotide termination method.
A tau-red fluorescent protein (RFP) expression construct was generated as follows.
The full-length wt and mutant human tau cDNAs (four-repeat tau cDNAs) lacking exons 2 and 3 (0N4R), incorporated into the EcoRI and BglII sites in pCXN2, were prepared as described previously (25) . The tau-encoding sequence without stop codon was amplified by PCR using the forward primer 5'-GCTTCCATGGCTCTGAATAATGTCACCATG-3' and the reverse primer 5'-TTTTGTCGACTAGAGTACAGAGAGGTCA-3'. The PCR product was then digested with EcoRI and XhoI, and subcloned into the EcoRI and XhoI sites of pDsRed-N1 (BD Biosciences). Likewise, cDNAs encoding the amino-terminal half (NTH; residues 2-220 of the 441-residue isoform; GenBank accession number NP_005901) and the carboxyl-terminal half (CTH; residues 251-419) of tau, the carboxyl-terminal fragment of MAP2 (CTF; residues 1668-1805 of the 1827-residiue MAP2; GenBank accession number NP_002365) and the CTF of MAP4 (residues 1001-1136 of the 1152-residue MAP4; GenBank accession number AAA59553) were also prepared by PCR. These cDNAs were cloned into pDsRed1-N1 in frame with the DsRed1-coding sequence. Confocal immunofluorescence microscopy-The cells on chamber slides (Nalge Nunc International, Nperville, IL) were fixed with cold methanol or 4% paraformaldehyde, followed by permeabilization with 0.1% Triton X-100 in PBS. The fixed cells were probed with rat anti-tubulin monoclonal antibody (MAB1864, 1 µg/ml, Chemicon international, Temecula, CA), followed by incubation with goat anti-rat IgG (H+L) conjugated with Alexa Fluor 647 (1:1000; Molecular Probes, Eugene, OR), as described previously (25) . Specimens were observed under a confocal microscope (TCS SP2; Leica Microsystems, Wetzlar, Germany).
Brain protein preparation-Control mouse brain at age of 8 weeks was homogenized in 10 volumes of ice-cold 50 mM Tris-HCl buffer (pH 7.4) containing 150 mM NaCl and protease inhibitors (Complete EDTA-free, Roche Diagnostics, Mannheim, Germany) using a Teflon/glass homogenizer. The homogenate was centrifuged at 105,000 x g for 15 min at 4 ÚC, and the supernatant was saved for biochemical analyses. For preparing heat-stable fraction, the supernatant was heated to 100 ÚC for 10 min and cleared by centrifugation at 105,000 x g for 15 min. Protein concentrations were determined by the Bradford method (Bio-Rad, Hercules, CA).
Interaction of recombinant Gem GTPase and tauSoluble and heat-stable fractions
prepared from mouse brain homogenates were incubated at 4 ÚC for 1 h with glutathione-Sepharose beads that were prebound to 50 µg glutathione-S-transferase (GST) or GST-Gem GTPase as described previously (18) . Whether tau binds to GST or GST-Gem GTPase on glutathione-Sepharose was examined by western blotting using tau 1 (Chemicon international).
Results

Gem GTPase is upregulated in the brains of eight-week-old tau-deficient
mice-To identify transcripts with altered expression, the levels of ~11,000 mRNAs in the brains of tau-deficient mice were compared with those from the brain of control mice of the same ages. To minimize potential confounding factors, pooled RNA samples from control and tau-deficient mice were subjected to analysis of expression differences on Affymetrix GeneChip, as described in Experimental Procedures. This initial microarray screening suggested that the levels of 74 mRNAs including tau are significantly altered in the brains of eight-week-old tau-deficient mice (Supplemental Table S2 ).
Quantitative RT-PCR using five wt and five tau-deficient mice indicated that, of these transcripts, the levels of 13 mRNAs encoding transcription factors, cytokines, a rasrelated GTP-binding protein, protease inhibitors and a membrane protein were indeed increased (Supplemental Table S3 ).
Of those genes with upregulated expression, we selected Gem GTPase for further analysis, because it was significantly and consistently increased in tau-deficient mice.
The levels of Gem GTPase mRNA were most elevated at eight weeks of age in the brains of tau-deficient mice (P < 0.001, Student's t-test; Fig. 1 ), and did not differ significantly from those of control mice at one week or eight months of age (Fig. 1) .
Overexpression of Gem GTPase induces long cellular processes from CHO cells-Although the major function of Gem GTPase has not yet been determined, this protein
was recently shown to be a negative regulator of the Rho-Rho kinase pathway for cytoskeletal organization (18) . To gain more insight into the function of Gem GTPase, we examined the effects of its overexpression on the morphology of CHO cells. The cells were transfected with GFP-tagged Gem GTPase and/or RFP-tagged tau, and processed for fluorescence microscopy as described in Experimental Procedures.
First, we examined the intracellular localization of exogenous Gem GTPase and tau in CHO cells. When cells were fixed with paraformaldehyde, the fluorescence of GFP or RFP alone was distributed uniformly in the cytoplasm with occasional aggregation, suggesting that neither GFP nor RFP is bound to cytoskeletal components, such as MTs ( Fig. 2A) . In contrast, tau-RFP mainly colocalized with MTs ( Fig. 2B and Fig. 1SA ).
To confirm that tau binds to MTs, the cells were fixed with cold methanol to wash away cytosolic tau-RFP. This fixation protocol showed that most tau-RFP colocalized with MTs ( Fig. 1SB) , which suggested that the tau in the cytoplasm represents "overflowing" tau. In many cells transfected with tau-RFP cDNA, MT bundles were observed ( Fig. 2B and Fig. 1S ), but no other distinct morphological features were noted compared with non-transfectant cells ( Fig. 2A and B) . Thus, overexpression of GFP, RFP, and especially tau-RFP, induces no morphological changes in CHO cells.
In contrast, CHO cells overexpressing GFP-Gem GTPase and RFP displayed a remarkable alteration in their morphology. Each cell became highly elongated and often had one very long process (Fig. 2C ). Because this effect was not observed in the GFPor RFP-expressing control cells ( Fig. 2A) , we concluded that Gem GTPase induced this morphological change in CHO cells.
Surprisingly, the cell elongation induced by Gem GTPase was completely
suppressed by co-transfection with tau-RFP cDNA (Fig. 2D) . To localize the active region of tau that antagonizes the effect induced by Gem GTPase, either the aminoterminal half (NTH) or the carboxyl-terminal half (CTH) of tau that is fused to RFP was co-expressed with Gem GTPase. As shown in Fig. 2E and F, whereas the NTH of tau did not suppress the Gem-GTPase-induced cell elongation, the CTH of tau suppressed it completely. Thus, this suggests that the antagonistic effect is attributable to the MT-binding domain of tau.
One hundred CHO cells expressing both GFP and RFP were chosen in an unselected way and subjected to the quantification. The ratio of long axis (X)/ short axis (Y) of the cell was taken as an index for cell elongation; higher values indicate higher degrees of cell elongation. As shown in Fig. 3 , the mean X values for Gem GTPaseoverexpressing cells were remarkably high, compared with those for the control cells expressing only GFP or RFP (P < 0.01, Student's t-test). This effect was completely abolished by the co-expression of tau (P < 0.01).
A number of isoforms of tau are transcribed from a single gene by alternative splicing. Each isoform is generated by the following combinations: no insert, inclusion of exon 2-encoded insert or exons 2-and 3-encoded insert in the amino-terminal half (referred to as S, M, and L, respectively), and exclusion/inclusion of exon 10-encoded second repeat in the carboxyl-terminal half [referred to as three-repeat (3R) and fourrepeat (4R) tau, respectively]. This rather complicated splicing is developmentally regulated, and the species S3R that is expressed exclusively in the fetal brain is rapidly replaced by 4R isoforms after birth in rodent (26) (27) (28) . We examined whether the effects of the Gem GTPase are isoform-dependent. The L and M4R isoforms showed similar inhibitory activities against the effect induced by Gem GTPase (data not shown). The three-repeat tau also inhibited Gem-GTPase-induced cell elongation (data not shown).
These results are consistent with the assumption that the MT-binding domain of tau has the activity that antagonizes Gem-GTPase-induced cell elongation.
Antagonizing activity is attributable to the MT-binding domain of MAPs-The
MT-binding region of tau is composed of highly conserved 18-residue-long binding elements, each having a distinctive Pro-Gly-Gly-Gly motif (29) (30) (31) . The MT-binding motifs are also found in the CTFs of MAP2 and MAP4 (Fig. 4A and B) . We examined whether these two homologous MT-binding regions suppress Gem-GTPase-induced cell elongation. When GFP-Gem GTPase and MAP2 CTF-RFP were co-expressed, the elongated cell morphology was no longer observed ( Fig. 4C and D) . The MTbinding domain of MAP4 had also a similar inhibitory effect (Fig. 4E) . Whereas the Cterminal extensions of tau and MAP2 are highly homologous, that of MAP4 beyond the MT-binding domain is not homologous with the former (Fig. 4B) . These results indicate that the MT-binding domains but not the C-terminal extensions have these antagonistic activities, and suggest that those MAPs as well as tau may regulate the function of Gem GTPase in vivo.
To clarify whether the inhibitory effect of tau on cellular elongation is inherent to CHO cells, other cell lines were examined. HeLa, Neuro2a, or PC12 cells were transfected with either a GFP-Gem GTPase-or a GFP-(control) expressing construct, and the cell shape was evaluated 24 h later. Overexpression of Gem GTPase in HeLa cells caused a morphological change similar to that observed in CHO cells, but no such phenotype was observed in Neuro2a or PC12 cells (data not shown). We do not yet know whether this negative effect is due to the presence of low levels of tau in these cell lines.
Tau does not directly bind to Gem
GTPase-Finally, we asked whether there is a direct molecular interaction between Gem GTPase and tau. We sought to detect a potential interaction using recombinant glutathione S-transferase (GST)-Gem GTPase and tau in mouse brain extracts. Further, we used the tau in heat-treated mouse brain extract, because heat-treated tau must be free of tau-interacting proteins. In either case, we were unable to find any noticeable interaction between Gem GTPase and tau ( Fig.   5A and B) . In addition, the intracellular distribution of GFP-Gem GTPase and tau-RFP in transfected CHO cells was carefully assessed using a confocal microscope. When fixed with paraformaldehyde, the GFP-Gem GTPase was distributed diffusely in the cytoplasm, consistent with a previous report (18) . In contrast, tau-RFP almost completely colocalized with MTs (Fig. 5C) . Similar results were also obtained in the methanol-fixed cells (Fig. 5D) . All of the above results strongly suggest that there is no direct molecular interaction between Gem GTPase and tau. Because the function of Gem GTPase has not yet been determined, we looked for a possible cell-biological relationship between Gem GTPase and tau. We first found that
Discussion
Gem GTPase induces profound changes in the cell morphology in CHO cells. A similar cellular effect of Gem GTPase was reported in other cells, including human umbilical vein endothelial cells (HUVEC) and HEK-293 cells (19). In addition, Ges, another
Rad/Gem/Kir (RGK) family member and a human ortholog of mouse Rem1, was reported to induce endothelial cell sprouting (32) . Tau is indeed able to antagonize the effects induced by Gem GTPase, and this activity is localized to the MT-binding domain of tau (Fig. 2E and F) . The motifs of the domain are composed of highly conserved 18-amino acid repeat identified in tau (29) (30) (31) , which are also found in MAP2 and MAP4 (Fig. 4A and B) . Either of these MT-binding regions similarly antagonized the Gem GTPase-induced effect (Fig. 4) . These results indicate that cellular elongation, a Gem GTPase-induced phenotype, can be modulated by MTbinding domains of tau, MAP2, and MAP4. given as mean ± SD (n = 5). The levels of Gem GTPase mRNA were significantly elevated at eight weeks of age in the brains of tau-deficient mice (P < 0.001, Student's t-test), but did not differ significantly from those of control mice at one week or eight months of age. 
